Massive data dive reveals true cost of treating rare muscle disease
NCT ID NCT07378943
Summary
This study aimed to understand how three different treatments for spinal muscular atrophy (SMA) are actually used in the real world and what they cost the healthcare system. Researchers analyzed anonymous insurance claims data from over 4,100 patients who received one of the treatments between 2016 and 2024. The goal was to gather practical information on dosing patterns and long-term expenses, not to test a new therapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MUSCULAR ATROPHY, SPINAL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis
East Hanover, New Jersey, 07936, United States
Conditions
Explore the condition pages connected to this study.